TLR-dependent T cell activation in autoimmunity

Nature Reviews Immunology

Volumn 11, Issue 12, 2011, Pages 807-822

  Mills, Kingston H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR DISTRIBUTION; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATTERN RECOGNITION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; CELL DEATH; CYTOKINES; HOST-PATHOGEN INTERACTIONS; HUMANS; INFECTION; INFLAMMATION; INTESTINES; LYMPHOCYTE ACTIVATION; MICE; MOLECULAR MIMICRY; ORGAN SPECIFICITY; SELF TOLERANCE; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH17 CELLS; TOLL-LIKE RECEPTORS;

EID: 82255191977     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3095     Document Type: Review

References (120)

1. Janeway, C. A. Jr & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002). (Pubitemid 34293424)
2. Mills, K. H. Induction, function and regulation of IL-17-producing T cells. Eur. J. Immunol. 38, 2636-2649 (2008).
3. Wing, K. & Sakaguchi, S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nature Immunol. 11, 7-13 (2010).
4. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006). (Pubitemid 43261452)
5. Hennessy, E. J., Parker, A. E. & O'Neill, L. A. Targeting Toll-like receptors: emerging therapeutics? Nature Rev. Drug Discov. 9, 293-307 (2010).
6. Sutton, C. E. et al. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity 31, 331-341 (2009).
7. Van Beelen, A. J. et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 27, 660-669 (2007).
8. Lalor, S. J. et al. Caspase-1-processed cytokines IL-1β and IL-18 promote IL-17 production by γδ and CD4 T cells that mediate autoimmunity. J. Immunol. 186, 5738-5748 (2011).
9. Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485-498 (2009).
10. Prinz, M. et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 116, 456-464 (2006). (Pubitemid 43228363)
11. Abdollahi-Roodsaz, S. et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest. 118, 205-216 (2008).
12. Brereton, C. F., Sutton, C. E., Lalor, S. J., Lavelle, E. C. & Mills, K. H. Inhibition of ERK MAPK suppresses IL-23-and IL-1-driven IL-17 production and attenuates autoimmune disease. J. Immunol. 183, 1715-1723 (2009).
13. Jarnicki, A. G. et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J. Immunol. 180, 3797-3806 (2008).
14. Conroy, H., Marshall, N. A. & Mills, K. H. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27, 168-180 (2008).
15. Higgins, S. C. & Mills, K. H. TLR, NLR agonists, and other immune modulators as infectious disease vaccine adjuvants. Curr. Infect. Dis. Rep. 12, 4-12 (2010).
16. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
17. Mangan, P. R. et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 441, 231-234 (2006).
18. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. & Stockinger, B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189 (2006). (Pubitemid 43214587)
19. Sutton, C., Brereton, C., Keogh, B., Mills, K. H. & Lavelle, E. C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203, 1685-1691 (2006). (Pubitemid 44036274)
20. Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910-1914 (2003). (Pubitemid 36801431)
21. Harrington, L. E. et al. Interleukin 17-producing CD4r effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6, 1123-1132 (2005). (Pubitemid 41541790)
22. Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunol. 6, 1133-1141 (2005). (Pubitemid 41541791)
23. Martin, B., Hirota, K., Cua, D. J., Stockinger, B. & Veldhoen, M. Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity 31, 321-330 (2009).
24. Rachitskaya, A. V. et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORγt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J. Immunol. 180, 5167-5171 (2008).
25. Takatori, H. et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med. 206, 35-41 (2009).
26. Murphy, A. C., Lalor, S. J., Lynch, M. A. & Mills, K. H. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav. Immun. 24, 641-651 (2010).
27. Park, Y., Park, S., Yoo, E., Kim, D. & Shin, H. Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility. Ann. NY Acad. Sci. 1037, 170-174 (2004). (Pubitemid 40299762)
28. Hong, J. et al. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J. Gastroenterol. Hepatol. 22, 1760-1766 (2007). (Pubitemid 47525075)
29. Van Heel, D. A. et al. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut 54, 1553-1557 (2005). (Pubitemid 41531770)
30. Kamradt, T., Goggel, R. & Erb, K. J. Induction, exacerbation and inhibition of allergic and autoimmune diseases by infection. Trends Immunol. 26, 260-267 (2005). (Pubitemid 41556849)
31. Serafini, B. et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204, 2899-2912 (2007). (Pubitemid 350179559)
32. Buljevac, D. et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125, 952-960 (2002). (Pubitemid 34464607)
33. Correale, J., Fiol, M. & Gilmore, W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 67, 652-659 (2006). (Pubitemid 44273613)
34. Saal, J. G. et al. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol. Int. 12, 147-151 (1992).
35. Saal, J. G. et al. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis Rheum. 42, 1485-1496 (1999). (Pubitemid 30265608)
36. Abraham, C. & Medzhitov, R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140, 1729-1737 (2011).
37. Wu, H. J. et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32, 815-827 (2010).
38. Atarashi, K. et al. ATP drives lamina propria TH17 cell differentiation. Nature 455, 808-812 (2008).
39. Feng, T., Wang, L., Schoeb, T. R., Elson, C. O. & Cong, Y. Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J. Exp. Med. 207, 1321-1332 (2010).
40. Herrmann, I. et al. Streptococcus pneumoniae infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. Infect. Immun. 74, 4841-4848 (2006). (Pubitemid 44157271)
41. Schrijver, I. A., Melief, M. J., Tak, P. P., Hazenberg, M. P. & Laman, J. D. Antigen-presenting cells containing bacterial peptidoglycan in synovial tissues of rheumatoid arthritis patients coexpress costimulatory molecules and cytokines. Arthritis Rheum. 43, 2160-2168 (2000).
42. Klasen, I. S. et al. The presence of peptidoglycan-polysaccharide complexes in the bowel wall and the cellular responses to these complexes in Crohn's disease. Clin. Immunol. Immunopathol. 71, 303-308 (1994).
43. Visser, L. et al. Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates. Am. J. Pathol. 169, 1671-1685 (2006). (Pubitemid 351181999)
44. Schrijver, I. A. et al. Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis. Brain 124, 1544-1554 (2001). (Pubitemid 32726768)
45. Bsibsi, M., Ravid, R., Gveric, D. & van Noort, J. M. Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 61, 1013-1021 (2002). (Pubitemid 35278723)
46. Rajan, N. & Langtry, J. A. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin. Exp. Dermatol. 31, 140-141 (2006).
47. Bach, J. F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347, 911-920 (2002).
48. Maizels, R. M. & Yazdanbakhsh, M. T-cell regulation in helminth parasite infections: implications for inflammatory diseases. Chem. Immunol. Allergy 94, 112-123 (2008).
49. Strachan, D. P. Family size, infection and atopy: the first decade of the "hygiene hypothesis". Thorax 55, S2-S10 (2000). (Pubitemid 30468238)
50. Walsh, K. P., Brady, M. T., Finlay, C. M., Boon, L. & Mills, K. H. Infection with a helminth parasite attenuates autoimmunity through TGF-β-mediated suppression of Th17 and Th1 responses. J. Immunol. 183, 1577-1586 (2009).
51. Ochoa-Reparaz, J. et al. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. J. Immunol. 185, 4101-4108 (2010).
52. Seong, S. Y. & Matzinger, P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nature Rev. Immunol. 4, 469-478 (2004). (Pubitemid 38745558)
53. Oppenheim, J. J. & Yang, D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359-365 (2005). (Pubitemid 40848537)
54. Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81, 1-5 (2007). (Pubitemid 46028489)
55. Yanai, H. et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462, 99-103 (2009).
56. Li, J. et al. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J. Rheumatol. 37, 766-775 (2010).
57. Chen, C. J. et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nature Med. 13, 851-856 (2007).
58. Farez, M. F. et al. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nature Immunol. 10, 958-964 (2009).
59. Sacre, S. M. et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am. J. Pathol. 170, 518-525 (2007). (Pubitemid 47339389)
60. Hoffmann, M. H. et al. Nucleic acid-stimulated antigen-presenting cells trigger T cells to induce disease in a rat transfer model of inflammatory arthritis. J. Autoimmun. 36, 288-300 (2011).
61. Marta, M., Andersson, A., Isaksson, M., Kampe, O. & Lobell, A. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur. J. Immunol. 38, 565-575 (2008).
62. Reynolds, J. M. et al. Toll-like receptor 2 signaling in CD4r T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 32, 692-702 (2010).
63. Ichikawa, H. T., Williams, L. P. & Segal, B. M. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169, 2781-2787 (2002). (Pubitemid 34921028)
64. Hall, J. A. et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 29, 637-649 (2008).
65. Touil, T., Fitzgerald, D., Zhang, G. X., Rostami, A. & Gran, B. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-β. J. Immunol. 177, 7505-7509 (2006). (Pubitemid 44846263)
66. Onta, T. et al. Induction of acute arthritis in mice by peptidoglycan derived from Gram-positive bacteria and its possible role in cytokine production. Microbiol. Immunol. 37, 573-582 (1993). (Pubitemid 23285973)
67. Frasnelli, M. E., Tarussio, D., Chobaz-Peclat, V., Busso, N. & So, A. TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res. Ther. 7, R370-R379 (2005).
68. Ronaghy, A. et al. Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J. Immunol. 168, 51-56 (2002). (Pubitemid 34014101)
69. Abdollahi-Roodsaz, S. et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum. 56, 2957-2967 (2007). (Pubitemid 47502742)
70. Su, S. B. et al. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J. Immunol. 175, 6303-6310 (2005). (Pubitemid 41598869)
71. Kim, H. S. et al. Toll-like receptor 2 senses β-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27, 321-333 (2007). (Pubitemid 47284922)
72. Summers, S. A. et al. Toll-like receptor 2 induces Th17 myeloperoxidase autoimmunity while Toll-like receptor 9 drives Th1 autoimmunity in murine vasculitis. Arthritis Rheum. 63, 1124-1135 (2011).
73. van der Fits, L. et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J. Immunol. 182, 5836-5845 (2009).
74. Evans, H. G., Suddason, T., Jackson, I., Taams, L. S. & Lord, G. M. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc. Natl Acad. Sci. USA 104, 17034-17039 (2007). (Pubitemid 350210986)
75. Higgins, S. C., Jarnicki, A. G., Lavelle, E. C. & Mills, K. H. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177, 7980-7989 (2006). (Pubitemid 44846315)
76. Acosta-Rodriguez, E. V. et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nature Immunol. 8, 639-646 (2007). (Pubitemid 46785128)
77. LeibundGut-Landmann, S. et al. Syk-and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nature Immunol. 8, 630-638 (2007).
78. Ivanov, I. I. et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337-349 (2008).
79. Tigno-Aranjuez, J. T., Jaini, R., Tuohy, V. K., Lehmann, P. V. & Tary-Lehmann, M. Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells. J. Immunol. 183, 5654-5661 (2009).
80. Waldner, H., Collins, M. & Kuchroo, V. K. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 113, 990-997 (2004). (Pubitemid 38544120)
81. Veldhoen, M., Hocking, R. J., Flavell, R. A. & Stockinger, B. Signals mediated by transforming growth factor-β initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nature Immunol. 7, 1151-1156 (2006). (Pubitemid 44594310)
82. Hansen, B. S., Hussain, R. Z., Lovett-Racke, A. E., Thomas, J. A. & Racke, M. K. Multiple Toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J. Neuroimmunol. 172, 94-103 (2006). (Pubitemid 43277494)
83. Peng, G. et al. Toll-like receptor 8-mediated reversal of CD4r regulatory T cell function. Science 309, 1380-1384 (2005). (Pubitemid 41209366)
84. Pasare, C. & Medzhitov, R. Toll pathway-dependent blockade of CD4rCD25f T cell-mediated suppression by dendritic cells. Science 299, 1033-1036 (2003). (Pubitemid 36222922)
85. Yang, Y., Huang, C. T., Huang, X. & Pardoll, D. M. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nature Immunol. 5, 508-515 (2004). (Pubitemid 38660463)
86. Kubo, T. et al. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J. Immunol. 173, 7249-7258 (2004). (Pubitemid 39628161)
87. den Haan, J. M., Kraal, G. & Bevan, M. J. Cutting edge: lipopolysaccharide induces IL-10-producing regulatory CD4r T cells that suppress the CD8f T cell response. J. Immunol. 178, 5429-5433 (2007). (Pubitemid 46674336)
88. Imanishi, T. et al. Cutting edge: TLR2 directly triggers Th1 effector functions. J. Immunol. 178, 6715-6719 (2007). (Pubitemid 46847393)
89. Marsland, B. J. et al. TLR ligands act directly upon T cells to restore proliferation in the absence of protein kinase C-θ signaling and promote autoimmune myocarditis. J. Immunol. 178, 3466-3473 (2007). (Pubitemid 46417611)
90. Melzer, N., Meuth, S. G. & Wiendl, H. CD8f T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB J. 23, 3659-3673 (2009).
91. Wong, C. K. et al. Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 159, 11-22 (2010).
92. Hornung, V. et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168, 4531-4537 (2002). (Pubitemid 34441357)
93. Cottalorda, A. et al. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur. J. Immunol. 36, 1684-1693 (2006). (Pubitemid 44089036)
94. Roark, C. L., Simonian, P. L., Fontenot, A. P., Born, W. K. & O'Brien, R. L. γδ T cells: an important source of IL-17. Curr. Opin. Immunol. 20, 353-357 (2008).
95. Caramalho, I. et al. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197, 403-411 (2003). (Pubitemid 36278597)
96. Crellin, N. K. et al. Human CD4r T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4rCD25f T regulatory cells. J. Immunol. 175, 8051-8059 (2005). (Pubitemid 41798367)
97. Sutmuller, R. P. et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116, 485-494 (2006). (Pubitemid 43228366)
98. Liu, H., Komai-Koma, M., Xu, D. & Liew, F. Y. Toll-like receptor 2 signaling modulates the functions of CD4r CD25f regulatory T cells. Proc. Natl Acad. Sci. USA 103, 7048-7053 (2006).
99. Round, J. L. et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332, 974-977 (2011).
100. Fort, M. M. et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J. Immunol. 174, 6416-6423 (2005). (Pubitemid 40663835)
101. Ungaro, R. et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1167-G1179 (2009).
102. Mullarkey, M. et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304, 1093-1102 (2003). (Pubitemid 36254422)
103. Eisai Co., Ltd. Phase III study for severe sepsis treatment eritoran (E5564) does not meet primary endpoint. Eisai Co., Ltd. [online], http://www.eisai.com/news/enews201108pdf.pdf (2011).
104. Arslan, F. et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic Toll-like receptor-2 and reduced by systemic administration of a novel anti-Toll-like receptor-2 antibody. Circulation 121, 80-90 (2010).
105. Lazzaro, B. P. & Rolff, J. Immunology. Danger, microbes, and homeostasis. Science 332, 43-44 (2011).
106. Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665-1674 (2008). (Pubitemid 351671883)
107. US Food and Drug Administration. FDA briefing document: supplemental BLA 125319. FDA [online], http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM259596.pdf (2011).
108. Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003). (Pubitemid 36227625)
109. Vermeire, K. et al. Accelerated collagen-induced arthritis in IFN-γ receptor-deficient mice. J. Immunol. 158, 5507-5513 (1997). (Pubitemid 127681260)
110. Krakowski, M. & Owens, T. Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26, 1641-1646 (1996). (Pubitemid 26230015)
111. Komiyama, Y. et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177, 566-573 (2006). (Pubitemid 43939170)
112. Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240 (2005). (Pubitemid 40189432)
113. Murphy, C. A. et al. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951-1957 (2003). (Pubitemid 38032126)
114. Kroenke, M. A., Carlson, T. J., Andjelkovic, A. V. & Segal, B. M. IL-12-and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205, 1535-1541 (2008). (Pubitemid 351962016)
115. Luger, D. et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 205, 799-810 (2008). (Pubitemid 351549879)
116. Panitch, H. S., Hirsch, R. L., Haley, A. S. & Johnson, K. P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1, 893-895 (1987).
117. Masters, S. L. et al. Regulation of interleukin-1β by interferon-γ is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep. 11, 640-646 (2010).
118. Annunziato, F. et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204, 1849-1861 (2007). (Pubitemid 47240944)
119. Fang, J. et al. The role of TLR2, TRL3, TRL4, and TRL9 signaling in the pathogenesis of autoimmune disease in a retinal autoimmunity model. Invest. Ophthalmol. Vis. Sci. 51, 3092-3099 (2010).
120. Yoshino, S., Sasatomi, E. & Ohsawa, M. Bacterial lipopolysaccharide acts as an adjuvant to induce autoimmune arthritis in mice. Immunology 99, 607-614 (2000). (Pubitemid 30201008)